We have collected information about Targeted Delivery Of Rnai Therapeutics For Cancer Therapy for you. Follow the links to find out details on Targeted Delivery Of Rnai Therapeutics For Cancer Therapy.
https://www.ncbi.nlm.nih.gov/pubmed/21143026
1. Nanomedicine (Lond). 2010 Dec;5(10):1483-6. doi: 10.2217/nnm.10.124. Targeted delivery of RNAi therapeutics for cancer therapy. Li J, Huang L.Author: Jun Li, Leaf Huang
https://www.researchgate.net/publication/49669080_Targeted_delivery_of_RNAi_therapeutics_for_cancer_therapy
Of special interest are RNAi-based drug target discovery and validation, delivery systems for RNAi-based drugs, such as nanoparticles, rabies virus protein-based vehicles, and bacteriophages for...
https://www.nature.com/articles/s41467-018-03705-y
Apr 12, 2018 · Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials.Author: Daniel Rosenblum, Nitin Joshi, Nitin Joshi, Wei Tao, Jeffrey M. Karp, Jeffrey M. Karp, Dan Peer
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978219/
Mar 30, 2007 · The use of RNAi for cancer therapeutics could revolutionize treatment of this devastating disease. The challenges for cancer are not dissimilar to those faced for other diseases, and include finding good targets, delivery and minimizing toxicity.
https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-017-0683-y
Jul 28, 2017 · Since the expression and functionality of siRNAs and miRNAs are significantly reduced in cancer cells, RNAi is an attractive target for the development of innovative therapeutics. However, the main obstacle to achieving gene silencing in vivo using RNAi techniques is the delivery of therapeutic RNAi molecules [26].Author: Yong Xin, Min Huang, Wen Wen Guo, Qian Huang, Long zhen Zhang, Guan Jiang
https://augusta.pure.elsevier.com/en/publications/dendrimer-based-rna-interference-delivery-for-cancer-therapy
Abstract RNA interference (RNAi) has emerged as a promising tool for cancer treatment. A strenuous ongoing effort for translation of RNAi into clinically acceptable therapy is the development of vectors for efficient and targeted RNAi delivery. In this chapter, we review RNAi-based cancer treatment and the utility of dendrimers in RNAi delivery.
https://cancerres.aacrjournals.org/content/70/7/2571
Apr 01, 2010 · The dynamic properties of RNA interference (RNAi) in cancer biology have led investigators to pursue with significant interest its role in tumorigenesis and cancer therapy. We recently reported that decreased expression of key RNAi enzymes, Dicer and Drosha, in epithelial ovarian cancers was associated with poor clinical outcome in patients.Author: William M. Merritt, Menashe Bar-Eli, Anil K. Sood
https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)30677-3
May 01, 2013 · Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection RNA interference (RNAi)-based therapeutics have the potential to treat chronic hepatitis B virus (HBV) infection in a fundamentally different manner than current therapies.Author: Christine I. Wooddell, David B. Rozema, Markus Hossbach, Matthias John, Holly L. Hamilton, Qili Chu,...
Searching for Targeted Delivery Of Rnai Therapeutics For Cancer Therapy?
You can just click the links above. The data is collected for you.
